61368-63-6
Chemical Structure
TNP-ATP triethylammonium
- CAS. Nr.: 61368-63-6
- Formula:C40H77N12O19P3
- Molecular Weight:1123.03
IUPAC Name: tetrakis(triethylamine) ((3a'R,4'R,6'R,6a'R)-4'-(6-amino-9H-purin-9-yl)-2,4,6-trinitro-3a',4',6',6a'-tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxole]-2,4-dien-6'-yl)methyl triphosphate
InChIKey: LWJCIYVHICRLCD-VWNGUJKNSA-N
SMILES: CCN(CC)CC.CCN(CC)CC.CCN(CC)CC.CCN(CC)CC.NC1=NC=NC2=C1N=CN2[C@H](O3)[C@H](O4)[C@H](OC54C([N+]([O-])=O)=CC([N+]([O-])=O)=CC5[N+]([O-])=O)[C@H]3COP(O)(OP(OP(O)(O)=O)(O)=O)=O
Biological Activity: TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TNP-ATP triethylammonium | 98.7% | TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Honore P, et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain. 2002 Mar;96(1-2):99-105. [Content Brief]
- [2]. Xiao J, et al. TNP-ATP is Beneficial for Treatment of Neonatal Hypoxia-Induced Hypomyelination and Cognitive Decline. Neurosci Bull. 2016;32(1):99-107. [Content Brief]
